Arvinas (ARVN) Change in Accured Expenses (2017 - 2026)
Arvinas (ARVN) posted quarterly Change in Accured Expenses of -$6.8 million for Q1 2026, down 750.0% year-over-year from $1.0 million in Q1 2025, and down 142.5% quarter-over-quarter from $16.0 million in Q4 2025.
Analysis
Arvinas (ARVN) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Arvinas' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$6.8 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 750.0% year-over-year to -$6.8 million; the TTM figure through Mar 2026 stood at -$7.7 million (down 22.22% YoY), while the FY2025 annual figure was -$1.7 million, up 91.98% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$6.8 million, down from $16.0 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $25.2 million in Q4 2022, with the low at -$16.8 million in Q2 2025.
- The 5-year median for Change in Accured Expenses is -$100000.0 (2025), against an average of $458823.5.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses jumped 3750.0% in 2022, then sank 1033.33% in 2025.
- Arvinas' Change in Accured Expenses stood at $25.2 million in 2022, then plunged by 94.84% to $1.3 million in 2023, then tumbled by 476.92% to -$4.9 million in 2024, then surged by 426.53% to $16.0 million in 2025, then tumbled by 142.5% to -$6.8 million in 2026.
- Business Quant data shows ARVN's Change in Accured Expenses at -$6.8 million in Q1 2026, $16.0 million in Q4 2025, and -$100000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - | -10.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.10 Mn |
| Mar 31, 2026 | -6.80 Mn |
| Dec 31, 2025 | 16.00 Mn |
| Sep 30, 2025 | -100,000.00 |
| Jun 30, 2025 | -16.80 Mn |
| Mar 31, 2025 | -800,000.00 |
| Dec 31, 2024 | -4.90 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | -15.70 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 16.60 Mn |
| Jun 30, 2023 | 8.20 Mn |
| Mar 31, 2023 | -8.80 Mn |
| Dec 31, 2022 | 25.20 Mn |
| Sep 30, 2022 | 7.70 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Mar 31, 2022 | -15.60 Mn |
| Dec 31, 2021 | 35.50 Mn |
| Sep 30, 2021 | 200,000.00 |